These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 10762138

  • 1. Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment.
    Hirsch EC.
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S115-20; discussion S120-1. PubMed ID: 10762138
    [Abstract] [Full Text] [Related]

  • 2. Plasticity of nerve afferents to nigrostriatal neurons in Parkinson's disease.
    Anglade P, Tsuji S, Javoy-Agid F, Agid Y, Hirsch EC.
    Ann Neurol; 1995 Feb; 37(2):265-72. PubMed ID: 7847868
    [Abstract] [Full Text] [Related]

  • 3. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
    Carlsson T, Carta M, Muñoz A, Mattsson B, Winkler C, Kirik D, Björklund A.
    Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
    [Abstract] [Full Text] [Related]

  • 4. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity?
    Calabresi P, Giacomini P, Centonze D, Bernardi G.
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S60-8; discussion S68-9. PubMed ID: 10762133
    [Abstract] [Full Text] [Related]

  • 5. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P, Tremblay L, Féger J, Hirsch EC.
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [Abstract] [Full Text] [Related]

  • 6. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA, Dostrovsky JO, Moro E, Hodaie M, Lozano AM, Hutchison WD.
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [Abstract] [Full Text] [Related]

  • 7. [Neuroplasticity and Parkinson disease].
    Viallet F, Witjas T.
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S42-8. PubMed ID: 12690663
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Interactions of exogenous L-dopa with nigrostriatal dopaminergic neurons in Parkinson's disease.
    Melamed E.
    Adv Neurol; 1990 Dec; 53():61-6. PubMed ID: 2173376
    [No Abstract] [Full Text] [Related]

  • 10. Mechanism of action of short- and long-term L-DOPA treatment in parkinsonism: role of the surviving nigrostriatal dopaminergic neurons.
    Melamed E, Hefti F.
    Adv Neurol; 1984 Dec; 40():149-57. PubMed ID: 6695591
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning.
    Guigoni C, Dovero S, Aubert I, Li Q, Bioulac BH, Bloch B, Gurevich EV, Gross CE, Bezard E.
    Eur J Neurosci; 2005 Jul; 22(1):283-7. PubMed ID: 16029219
    [Abstract] [Full Text] [Related]

  • 13. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.
    Di Monte DA, McCormack A, Petzinger G, Janson AM, Quik M, Langston WJ.
    Mov Disord; 2000 May; 15(3):459-66. PubMed ID: 10830409
    [Abstract] [Full Text] [Related]

  • 14. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
    St-Hilaire M, Landry E, Lévesque D, Rouillard C.
    Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973
    [Abstract] [Full Text] [Related]

  • 15. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
    Encarnacion EV, Hauser RA.
    Eur Neurol; 2008 Nov; 60(2):57-66. PubMed ID: 18480609
    [Abstract] [Full Text] [Related]

  • 16. [Neurobiologic and pharmacologic studies on the pathogenesis of Parkinson disease].
    Brücke T, Riederer P.
    Wien Med Wochenschr; 1986 Aug 31; 136(15-16):401-8. PubMed ID: 2878540
    [Abstract] [Full Text] [Related]

  • 17. Dopamine-mediated gene regulation in models of Parkinson's disease.
    Gerfen CR.
    Ann Neurol; 2000 Apr 31; 47(4 Suppl 1):S42-50; discussion S50-2. PubMed ID: 10762131
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Clinical physiology of dopa dyskinesia.
    Hallett M.
    Ann Neurol; 2000 Apr 31; 47(4 Suppl 1):S147-50; discussion S150-3. PubMed ID: 10762142
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.